Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023
Portfolio Pulse from Benzinga Newsdesk
Exact Sciences Corp. (NASDAQ:EXAS) will present late-breaking data from the BLUE-C pivotal trial on next-generation Cologuard at the American College of Gastroenterology (ACG) Annual Meeting in October 2023. The company will also present further evidence supporting the cost-effectiveness and performance of next-generation Cologuard.
October 09, 2023 | 10:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Exact Sciences' presentation of late-breaking data on next-generation Cologuard at the ACG Annual Meeting could potentially boost investor confidence in the company's product pipeline.
The presentation of late-breaking data from a pivotal trial is typically a significant event for a biotech company like Exact Sciences. If the data is positive, it could boost investor confidence in the company's product pipeline and potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100